Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase

Cellular and Molecular Life Sciences

Volumn 72, Issue 19, 2015, Pages 3731-3746

  Mathieu, Véronique ^a   Chantôme, Aurélie ^b   Lefranc, Florence ^c   Cimmino, Alessio ^d   Miklos, Walter ^e   Paulitschke, Verena ^f   Mohr, Thomas ^e   Maddau, Lucia ^g   Kornienko, Alexander ^h   Berger, Walter ^e   Vandier, Christophe ^b   Evidente, Antonio ^d   Delpire, Eric ⁱ   Kiss, Robert ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b UNIVERSITÉ DE TOURS   (France)

^c ERASME HOSPITAL   (Belgium)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f Universitatsklinik fur Dermatologie   (Austria)

^g UNIVERSITY OF SASSARI   (Italy)

^h Texas State University   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anion exchanger; Apoptosis; Cell volume; Cl HCO3 ; Ion transporter; Melanoma; NKCC1; Sphaeropsidin A

Indexed keywords

ANTINEOPLASTIC AGENT; SPHAEROPSIDIN A; UNCLASSIFIED DRUG; DITERPENE; PROPIDIUM IODIDE; TRYPAN BLUE;

ANIMAL CELL; ANION EXCHANGE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL DAMAGE; CELL MEMBRANE POTENTIAL; CELLULAR PARAMETERS; CELLULAR SHRINKAGE; CONTROLLED STUDY; DIPLODIA; DIPLODIA CUPRESSI; DRUG IDENTIFICATION; DRUG STRUCTURE; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LC50; MELANOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; REGULATORY VOLUME INCREASE; ANIMAL; CELL SIZE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; HEK293 CELL LINE; ION TRANSPORT; TUMOR CELL LINE; VIDEO MICROSCOPY; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SIZE; DITERPENES; DRUG RESISTANCE, NEOPLASM; HEK293 CELLS; HUMANS; ION TRANSPORT; MICE; MICROSCOPY, VIDEO; MOLECULAR STRUCTURE; PROPIDIUM; TRYPAN BLUE;

EID: 84941225274     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-015-1902-6     Document Type: Article

References (55)

1. Buti S, Bersanelli M, Sikokis A, Maines F, Facchinetti F, Bria E, Ardizzoni A, Tortora G, Massari F (2013) Chemotherapy in metastatic renal cell carcinoma today? A systematic review. Anticancer Drugs 24:535-554
2. Luke JJ, Schwartz GK (2013) Chemotherapy in the management of advanced cutaneous malignant melanoma. Clin Dermatol 31:290-297
3. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM (2011) Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 16:5-24
4. Sullivan RJ, Flaherty KT (2014) Major therapeutic developments and current challenges in advanced melanoma. Br J Dermatol 170:36-44
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA (2011) BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
6. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P, Mirakhur B, Guckert ME, Goodman V, Chapman PB (2012) Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365
7. Sullivan RJ, Flaherty KT (2013) Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer 49:1297-1304
8. Iacovelli R, Alesini D, Palazzo A, Trenta P, Santoni M, De Marchis L, Cascinu S, Naso G, Cortesi E (2014) Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev 40:271-275
9. Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C (2012) Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther 12:1571-1577
10. Ravaud A, Gross-Goupil M (2012) Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. Cancer Treat Rev 38:996-1003
11. Calvo E, Ravaud A, Bellmunt J (2013) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat Rev 39:366-374
12. Figlin RA, Kaufmann I, Brechbiel J (2013) Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors. Int J Cancer 133:788-796
13. Cuddapah VA, Sontheimer H (2011) Ion channels and transporters in cancer. 2. Ion channels and the control of cancer cell migration. Am J Physiol Cell Physiol 301:C541-C549
14. Hoffmann EK, Lambert IH (2014) Ion channels and transporters in the development of drug resistance in cancer cells. Phil Trans R Soc B 369:20130109
15. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75:311-335
16. Cragg GM, Newman DJ (2013) Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830:3670-3695
17. Cragg GM, Grothaus PG, Newman DJ (2009) Impact of natural products on developing new anti-cancer agents. Chem Rev 109:3012-3043
18. Sparapano L, Bruno G, Fierro O, Evidente A (2004) Studies on structure-activity relationship of sphaeropsidins A-F, phytotoxins produced by Sphaeropsis sapinea f. sp. cupressi. Phytochemistry 65:189-198
19. Andolfi A, Maddau L, Basso S, Linaldeddu BT, Cimmino A, Scanu B, Deidda A, Tuzi A, Evidente A (2014) Diplopimarane, a 20-nor-ent-pimarane produced by the oak pathogen Diplodia quercivora. J Nat Prod 77:2352-2360
20. Weber RW, Kappe R, Paululat T, Mösker E, Anke H (2007) Anti-Candida metabolites from endophytic fungi. Phytochemistry 68:886-8892
21. Wang XN, Bashyal BP, Wijeratne EM, U'Ren JM, Liu MX, Gunatilaka MK, Arnold AE, Gunatilaka AA (2011) Smardaesidins A-G, isopimarane and 20-nor-isopimarane diterpenoids from Smardaea sp., a fungal endophyte of the moss Ceratodon purpureus. J Nat Prod 74:2052-2061
22. Lallemand B, Masi M, Maddau L, De Lorenzi M, Dam R, Cimmino A, Moreno y Banuls L, Andolfi A, Kiss R, Mathieu V, Evidente A (2012) Evaluation of in vitro anticancer activity of sphaeropsidins A-C, fungal rearranged pimarane diterpenes, and semisynthetic derivatives. Phytochem Lett 5:770-775
23. Mathieu V, Le Mercier M, De Neve N, Sauvage S, Gras T, Roland I, Lefranc F, Kiss R (2007) Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127:2399-2410
24. Chantome A, Girault A, Potier M, Collin C, Vaudin P, Pagès JC, Vandier C, Joulin V (2009) KCa2.3 channel-dependent hyperpolarization increases melanoma cell motility. Exp Cell Res 315:3620-3630
25. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092
26. Frédérick R, Bruyère C, Vancraeynest C, Reniers J, Meinguet C, Pochet L, Backlund A, Masereel B, Kiss R, Wouters J (2012) Novel trisubstituted harmine derivatives with original in vitro anticancer activity. J Med Chem 55:6489-6501
27. Mathieu V, Van Den Berge E, Ceusters J, Konopka T, Cops A, Bruyère C, Pirker C, Berger W, Trieu-Van T, Serteyn D, Kiss R, Robiette R (2013) New 5-aryl-1H-imidazoles display in vitro antitumor activity against apoptosis-resistant cancer models, including melanomas, through mitochondrial targeting. J Med Chem 56:6626-6637
28. Mijatovic T, Jungwirth U, Heffeter P, Hoda MA, Dornetshuber R, Kiss R, Berger W (2009) The Na+/K+-ATPase is the Achilles heel of multi-drug-resistant cancer cells. Cancer Lett 282:30-34
29. Remillard CV, Yuan JXJ (2004) Activation of K+ channels: an essential pathway in programmed cell death. Am J Physiol Lung Cell Mol Physiol 286:L49-L67
30. Okada Y, Shimizu T, Maeno E, Tanabe S, Wang X, Takahashi N (2006) Volume-sensitive chloride channels involved in apoptotic volume decrease and cell death. J Membr Biol 209:21-29
31. Okada Y, Maeno E (2001) Apoptosis, cell volume regulation and volume-regulatory chloride channels. Comp Biochem Physiol A: Mol Integr Physiol 130:377-383
32. 2+ mobilization is a prerequisite to apoptosis in HeLa cells. Apoptosis 17:821-831
33. O'Neill WC (1999) Physiological significance of volume-regulatory transporters. Am J Physiol 276:C995-C1011
34. - concentration. J Physiol 592:4099-4114
35. Hoffmann EK (2011) Ion channels involved in cell volume regulation: effects on migration, proliferation, and programmed cell death in non adherent EAT cells and adherent ELA cells. Cell Physiol Biochem 28:1061-1078
36. Speers AG, Lwaleed BA, Featherstone JM, Sallis BJ, Cooper AJ (2006) Furosemide reverses multidrug resistance status in bladder cancer cells in vitro. J Clin Pathol 59:912-915
37. Algharabil J, Kintner DB, Wang Q, Begum G, Clark PA, Yang SS, Lin SH, Kahle KT, Kuo JS, Sun D (2012) Inhibition of Na[+]-K[+]-2Cl[-] cotransporter isoform 1 accelerates temozolomide-mediated apoptosis in glioblastoma cancer cells. Cell Physiol Biochem 30:33-48
38. - cotransport in primary afferent neurons. J Physiol 588:3365-3373
39. + exchange activities in renal carcinoma cells. Physiol Genomics 5:119-128
40. Lee AH, Tannock IF (1998) Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res 58:1901-1908
41. Roepe PD, Wei LY, Cruz J, Carlson D (1993) Lower electrical membrane potential and altered pHi homeostasis in multidrug-resistant (MDR) cells: further characterization of a series of MDR cell lines expressing different levels of P-glycoprotein. Biochemistry 32:11042-11056
42. Roepe PD, Weisburg JH, Luz JG, Hoffman MM, Wei LY (1994) Novel Cl(-)-dependent intracellular pH regulation in murine MDR 1 transfectants and potential implications. Biochemistry 33:11008-11015
43. 3 exchange in Chinese hamster ovary cells. Biochemistry 33:7239-7249
44. Poulsen KA, Andersen EC, Hansen CF, Klausen TK, Hougaard C, Lambert IH, Hoffmann EK (2010) Deregulation of apoptotic volume decrease and ionic movements in multidrug-resistant tumor cells: role of chloride channels. Am J Physiol Cell Physiol 298:C14-C25
45. Liu CJ, Hwang JM, Wu TT, Hsieh YH, Wu CC, Hsieh YS, Tsai CH, Wu HC, Huang CY, Liu JY (2008) Anion exchanger inhibitor DIDS induces human poorly-differentiated malignant hepatocellular carcinoma HA22T cell apoptosis. Mol Cell Biochem 308:117-125
46. Hwang JM, Kao SH, Hsieh YH, Li KL, Wang PH, Hsu LS, Liu JY (2009) Reduction of anion exchanger 2 expression induces apoptosis of human hepatocellular carcinoma cells. Mol Cell Biochem 327:135-144
47. Malumbres R, Lecanda J, Melero S, Ciesielczyk P, Prieto J, Medina JF (2003) HNF1alpha upregulates the human AE2 anion exchanger gene (SLC4A2) from an alternate promoter. Biochem Biophys Res Commun 311:233-240
48. Pedersen SF, Hoffmann EK, Novak I (2013) Cell volume regulation in epithelial physiology and cancer. Front Physiol 4:233
49. Haas BR, Sontheimer H (2010) Inhibition of the sodium-potassium-chloride cotransporter isoform-1 reduces glioma invasion. Cancer Res 70:5597-5606
50. - cotransporter facilitates glioma migration. Mol Cancer 13:31
51. Haas BR, Cuddapah VA, Watkins S, Rohn KJ, Dy TE, Sontheimer H (2011) With-No-Lysine Kinase 3 (WNK3) stimulates glioma invasion by regulating cell volume. Am J Physiol Cell Physiol 301:C1150-C1160
52. Pogorevici A, Velciov SM, Secrii RV (2007) The molecular and physiopathological mechanisms involved in response reduction to chronic diuretics therapy. TMJ 57:58-67
53. - co-transporters. Biochem J 458:559-573
54. - exchanger antagonist, stimulates fluid absorption across basolateral surface of the retinal pigment epithelium. BMC Ophthalmol 11:33
55. Wilson MC, Meredith D, Bunnun C, Sessions RB, Halestrap AP (2009) Studies on the DIDS-binding site on monocarboxylate transporter 1 suggest a homology model of the open conformation and a plausible translocation cycle. J Biol Chem 284:20011-20021